FDA
approval
· 2018-04-18
FDA Approved: TYSABRI — Supplemental Application (Biogen Inc.)
Summary
FDA approved Biogen's supplemental application for TYSABRI (natalizumab).
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
SUPPL AP for TYSABRI (NATALIZUMAB)